The efficacy and feasibility of the repeated intraperitoneal Paclitaxel +systemic TS-1 and Paclitaxel for far advanced or recurrent gastric cancer: Phase I/II trial.

The efficacy and feasibility of the repeated intraperitoneal Paclitaxel +systemic TS-1 and Paclitaxel for far advanced or recurrent gastric cancer: Phase I/II trial. - The clinical effects of additional repeated intraperitoneal Paclitaxel for advanced gastric cancer.

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000636

Enrollment

Registered

2008-08-30

Start date

2006-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Far advanced or recurrent gastric cancer

Interventions

1.Oral TS-1 80mg/m2 every day 2.Intravenous Paclitaxel 50mg/m2 every week 3.intraperitoneal Paclitaxel every week 2 week administration and 1 week off x3 cycles

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-resectable gastric cancer with peritoneal dissemination, or positive peritoneal cytology.

Exclusion criteria

Exclusion criteria: Other hematogeneous metastasis multiple cancers other cases who are decided to be inappropriate for the clinical trial by doctors.

Design outcomes

Primary

Measure	Time frame
side effects 1-year survival	—

Secondary

Measure	Time frame
plasma level of taxol response rate Duration of overall Response Duration of complete Response Duration of Stable DiseaseTime To Progression	—

Countries

Japan

Contacts

Public ContactJoji Kitayama

The University of Tokyo Department of Surgical Oncology

kitayama-1SU@h-u-tokyo.ac.jp03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026